🇺🇸 FDA
Patent

US 9211302

Modulation of LRCH4 activity and therapeutic application thereof

granted A61KA61K31/713A61K38/1709

Quick answer

US patent 9211302 (Modulation of LRCH4 activity and therapeutic application thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/713, A61K38/1709, A61K39/3955, A61P